LY reduced gene expression of LGALS1 in the liver and in subcutaneous adipose tissue in obese mice. Modulation of S6K1 may be a target for treatment of obesity, dyslipidaemia and liver steatosis in humans. This evidence concerns the gene LGALS1 and Obesity.